KRAS and lung cancer: In lung cancer, EGFR mutations were detected in 11.1% of samples, none of which was mutated for KRAS. Despite the small size and heterogeneity of our sample, this percentage is close to the 16.6% reported in a large-scale screening for EGFR mutations in Spanish lung cancer patients [5].